Analysed APREA THERAPEUTICS INC (APRE:NASDAQ) News Sources
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
01-04-2026
yahoo.com
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
30-03-2026
yahoo.com
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
16-03-2026
yahoo.com
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
18-02-2026
yahoo.com
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
17-02-2026
yahoo.com
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
12-02-2026
yahoo.com
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
04-02-2026
yahoo.com
What is the current price of APREA THERAPEUTICS INC (APRE:NASDAQ)?
The current price of APREA THERAPEUTICS INC (APRE:NASDAQ) is $0.9168.
APREA THERAPEUTICS INC (APRE:NASDAQ) absolute price change since previous trading day?
The absolute price change of APREA THERAPEUTICS INC (APRE:NASDAQ) since the previous trading day is $0.1828.
APREA THERAPEUTICS INC (APRE:NASDAQ) percentage price change since previous trading day?
The percentage price change of APREA THERAPEUTICS INC (APRE:NASDAQ) since the previous trading day is 24.9046%.
What is the most recent average sentiment score for APREA THERAPEUTICS INC (APRE:NASDAQ)?
The most recent average sentiment score for APREA THERAPEUTICS INC (APRE:NASDAQ) is 86 out of 100.
What is the most recent average sentiment for APREA THERAPEUTICS INC (APRE:NASDAQ)?
The most recent sentiment for APREA THERAPEUTICS INC (APRE:NASDAQ) is .
SEC-8K** Filing Available For APREA THERAPEUTICS INC (APRE:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.